Tumor Biology

, Volume 36, Issue 5, pp 3511–3520 | Cite as

ALCAM is indirectly modulated by miR-125b in MCF7 cells

  • H. Begum Akman
  • S. Duygu Selcuklu
  • Mark T. A. Donoghue
  • Shiva Akhavantabasi
  • Aysegul Sapmaz
  • Charles Spillane
  • M. Cengiz Yakicier
  • A. Elif Erson-Bensan
Research Article


MicroRNA (miRNA) deregulation is associated with various cancers. Among an expanding list of cancer-related miRNAs, deregulation of miR-125b has been well documented in many cancers including breast. Based on current knowledge, miR-125b is considered to be a tumor suppressor in breast cancers. While important messenger RNA (mRNA) targets have been defined for miR-125b, here, we aimed to further investigate direct/indirect consequences of miR-125b expression in breast cancer cells by using a transcriptome approach. Upon miR-125b expression, a total of 138 cancer-related genes were found to be differentially expressed in breast cancer cells. While only a few of these were predicted to be direct mRNA targets, majority of the gene expression changes were potentially downstream and indirect effects of miR-125b expression. Among these, activated leukocyte antigen molecule (ALCAM) mRNA and protein levels were found to be highly significantly increased upon miR-125b expression. Given the tumor suppressor role of miR-125b in our model system, upon silencing of ALCAM expression, cell proliferation rate re-increased in miR-125b-expressing cells. While ALCAM’s possible context-dependent roles are not clear in breast cancer, a diverse expression pattern of ALCAM mRNA was detected in a panel of breast cancer patient samples. Differentially expressed/regulated cancer-related genes upon miR-125b expression along with the significant increase of ALCAM are of future interest to understand how deregulated expression of miR-125b may have a tumor suppressor role in breast and other cancers.


miR-125b ALCAM Breast cancer PERP CTGF Microarray 



We would like to thank Dr. Q. Fan and Prof. Ofori-Acquah for sharing ALCAM promoter constructs, Dr. J. Weiner for ALCAM shRNA construct, and Serkan Tuna and Cansaran Saygılı for technical assistance. CS, MTA, and DS were supported by funding from Science Foundation Ireland, IRCSET, and Cancer Research Ireland. This research was funded by METU internal funds and partially by TUBITAK 108S381.

Conflicts of interest


Supplementary material

13277_2014_2987_MOESM1_ESM.pdf (126 kb)
Supp. Table 1 Breast cancer patient panel information. (PDF 126 kb)
13277_2014_2987_MOESM2_ESM.pdf (265 kb)
Supp. Table 2, 3 Significantly up-regulated (n=68) and down-regulated genes (n=70) in MCF7-125b cells. (PDF 265 kb)
13277_2014_2987_MOESM3_ESM.pdf (810 kb)
Supp. Fig. 1 Volcano plot represents the relationship between fold change and statistical significance. X-axis represents the log2 Fold Change between MCF7-EV and MCF7-miR-125b cells. The vertical axis represents the Log Odds (B-Statistic). (PDF 810 kb)
13277_2014_2987_MOESM4_ESM.pdf (257 kb)
Supp. Fig. 2 A. T47D cells stably transfected with miR-125b or with EV (empty vector, pSUPER). miR-125b expression levels were normalized to U6 expression. Two independent experiments were performed with triplicate replicates. The Student t-test was used for analyzing the data. Transfected cells were polyclonally selected. B. Cell proliferation assay (MTT) was performed in T47D cells, transfected with precursor miR-125b and Empty Vector (EV) as control. Experiment was performed with 4 replicates for each sample. All OD570 values were divided into that of day 1 for both miR-125b and EV cells. 10,000 cells were initially seeded into each well of 96-well cell culture plates and four replicates were used for each sample. C. Seven fold induction of ALCAM expression in MCF7-EV and MCF7-125b cells. Bands were quantified using ImageJ. D. ALCAM protein levels were detectable in T47D-EV cells and no apparent increase was detected upon miR-125b expression. (PDF 256 kb)


  1. 1.
    Bartel D. Micrornas: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMedGoogle Scholar
  2. 2.
    Erson A, Petty E. MicroRNAs in development and disease. Clin Genet. 2008;74:296–306.CrossRefPubMedGoogle Scholar
  3. 3.
    Erson AE, Petty EM. MiRNAs and cancer: new research developments and potential clinical applications. Cancer Biol Ther. 2009;8:2317–22.CrossRefPubMedGoogle Scholar
  4. 4.
    Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.CrossRefPubMedGoogle Scholar
  5. 5.
    Calin G, Croce C. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Iorio M, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–707.CrossRefPubMedGoogle Scholar
  7. 7.
    Bloomston M, Frankel W, Petrocca F, Volinia S, Alder H, Hagan J, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C, et al. Myeloid cell differentiation arrest by mir-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med. 2008;205:2499–506.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009;15:5473–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Selcuklu SD, Yakicier MC, Erson AE. An investigation of microRNAs mapping to breast cancer related genomic gain and loss regions. Cancer Genet Cytogenet. 2009;189:15–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Mattie M, Benz C, Bowers J, Sensinger K, Wong L, Scott G, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5:24.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Scott G, Goga A, Bhaumik D, Berger C, Sullivan C, Benz C. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA mir-125a or mir-125b. J Biol Chem. 2007;282:1479–86.CrossRefPubMedGoogle Scholar
  13. 13.
    Akhavantabasi S, Sapmaz A, Tuna S, Erson-Bensan AE. Mir-125b targets ARID3B in breast cancer cells. Cell Struct Funct. 2012;37:27–38.CrossRefPubMedGoogle Scholar
  14. 14.
    Guan Y, Yao H, Zheng Z, Qiu G, Sun K. Mir-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer ;2010.Google Scholar
  15. 15.
    Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, et al. Mir-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011;71:3552–62.CrossRefPubMedGoogle Scholar
  16. 16.
    Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2f3. Int J Cancer. 2011;128:1758–69.CrossRefPubMedGoogle Scholar
  17. 17.
    Ozek NS, Tuna S, Erson-Bensan AE, Severcan F. Characterization of microRNA-125b expression in MCF7 breast cancer cells by ATR-FTIR spectroscopy. Analyst. 2010;135:3094–102.CrossRefPubMedGoogle Scholar
  18. 18.
    Kauffmann A, Gentleman R, Huber W. Arrayqualitymetrics—a bioconductor package for quality assessment of microarray data. Bioinformatics. 2009;25:415–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21:2067–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Falcon S, Gentleman R. Using gostats to test gene lists for go term association. Bioinformatics. 2007;23:257–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Akhavantabasi S, Akman HB, Sapmaz A, Keller J, Petty EM, Erson AE. Usp32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers. Mamm Genome. 2010;21:388–97.CrossRefPubMedGoogle Scholar
  24. 24.
    Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time pcr experiments. Clin Chem U S. 2009;55:611–22.CrossRefGoogle Scholar
  25. 25.
    Gur-Dedeoglu B, Konu O, Bozkurt B, Ergul G, Seckin S, Yulug IG. Identification of endogenous reference genes for qrt-pcr analysis in normal matched breast tumor tissues. Oncol Res. 2009;17:353–65.CrossRefPubMedGoogle Scholar
  26. 26.
    Fleige S, Walf V, Huch S, Prgomet C, Sehm J, Pfaffl MW. Comparison of relative mrna quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett. 2006;28:1601–13.CrossRefPubMedGoogle Scholar
  27. 27.
    Wang J, Gu Z, Ni P, Qiao Y, Chen C, Liu X, et al. NF-kappab p50/p65 hetero-dimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop. Nucleic Acids Res. 2011;39:6440–55.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Jannie KM, Stipp CS, Weiner JA. ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells. PLoS One. 2012;7:e39330.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Degen WG, van Kempen LC, Gijzen EG, van Groningen JJ, van Kooyk Y, Bloemers HP, et al. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol. 1998;152:805–13.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res. 2008;151:122–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Burandt E, Bari Noubar T, Lebeau A, Minner S, Burdelski C, Jänicke F, Müller V, Terracciano L, Simon R, Sauter G, Wilczak W, Lebok P. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients. Oncol Rep. 2014.Google Scholar
  32. 32.
    Bowen MA, Aruffo AA, Bajorath J. Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions. Proteins. 2000;40:420–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Swart GW. Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 2002;81:313–21.CrossRefPubMedGoogle Scholar
  34. 34.
    Weidle UH, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics. 2010;7:231–43.PubMedGoogle Scholar
  35. 35.
    Graham K, de las Morenas A, Tripathi A, King C, Kavanah M, Mendez J, et al. Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br J Cancer. 2010;102:1284–93.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Jezierska A, Olszewski WP, Pietruszkiewicz J, Olszewski W, Matysiak W, Motyl T. Activated leukocyte cell adhesion molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit. 2006;12:BR245–56.PubMedGoogle Scholar
  37. 37.
    Tan F, Mosunjac M, Adams AL, Adade B, Taye O, Hu Y, et al. Enhanced down-regulation of ALCAM/CD166 in African-American breast cancer. BMC Cancer. 2014;14:715.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, et al. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol. 2006;59:403–9.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A. 2008;105:1608–13.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Dusek RL, Bascom JL, Vogel H, Baron S, Borowsky AD, Bissell MJ, et al. Deficiency of the P53/P63 target PERP alters mammary gland homeostasis and promotes cancer. Breast Cancer Res. 2012;14:R65.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Jacobson A, Cunningham JL. Connective tissue growth factor in tumor pathogenesis. Fibrogenesis Tissue Repair. 2012;5 Suppl 1:S8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • H. Begum Akman
    • 1
  • S. Duygu Selcuklu
    • 2
    • 3
  • Mark T. A. Donoghue
    • 2
    • 4
  • Shiva Akhavantabasi
    • 1
    • 5
  • Aysegul Sapmaz
    • 1
    • 6
  • Charles Spillane
    • 7
  • M. Cengiz Yakicier
    • 8
  • A. Elif Erson-Bensan
    • 1
  1. 1.Department of BiologyM.E.T.U.AnkaraTurkey
  2. 2.Genetics and Biotechnology Laboratory, School of Natural SciencesNational University of IrelandGalwayIreland
  3. 3.Memorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.Cold Spring Harbor LaboratoryCold Spring HarborUSA
  5. 5.Department of Molecular Biology and GeneticsYeni Yuzyil UniversityIstanbulTurkey
  6. 6.Division of Cell BiologyNetherlands Cancer InstituteAmsterdamNetherlands
  7. 7.Genetics and Biotechnology Laboratory, Plant & AgriBiosciences Research Centre (PABC), School of Natural SciencesNational University of IrelandGalwayIreland
  8. 8.Department of Molecular Biology and GeneticsAcibadem UniversityIstanbulTurkey

Personalised recommendations